表皮生长因子受体酪氨酸激酶抑制剂在野生型进展期非小细胞肺癌治疗中的地位

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Wild-Type Advanced Non-Small Cell Lung Carcer

摘要: 大部分进展期非小细胞肺癌患者为表皮生长因子受体野生型,在文献报道中,野生型患者普遍对表皮生长因子受体酪氨酸激酶抑制剂不敏感,但仍有临床研究发现,部分野生型患者可以从酪氨酸激酶抑制剂的治疗中获益。目前尚无预测因子能够预测表皮生长因子受体酪氨酸激酶抑制剂对野生型患者的疗效。

Abstract: The major proportion of advanced non-small cell lung carcer does not contain activating mutations in the epidermal growth factor receptor （EGFR）, which is called EGFR wild type （WT）. Despite EGFR-WT patients who lack the sensitivity of EGFR tyrosine kinase inhibitors （TKI）, there are some evidences demonstrating that some EGFR-WT patients can get benefit from EGFR-TKI. No prognostic biomarkers can predict outcomes of EGFR-WT treated by TKI so far.